Skip to main content

LABSCO Distributing Response Biomedical's Cardiovascular Test Products in US

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday a US distribution deal covering its cardiovascular portfolio of Ramp products.

Under the agreement, Louisville, Ky.-based Laboratory Supply Company (LABSCO) will distribute Ramp products in the US exclusively to hospital with less than 150 beds. The agreement is between Response Biomed's newly formed, wholly owned US subsidiary Response Point of Care and LABSCO for an initial period of three years, renewable upon mutual agreement.

Additional terms of the deal were not disclosed.

Privately held LABSCO distributes clinical laboratory products in the US.

LABSCO will initially market Response's cardiovascular POC tests panels on the Ramp Reader in all settings and on the Ramp 200 reader in laboratory settings. Response said it will continue to make the cardiovascular POC test panel on the Ramp 200 and Ramp Reader available outside the US. It also will continue marketing the Ramp Flu A+B Assay and Ramp RSV Assay on the Ramp 200 globally where approved by regulators.

The Ramp platform is a portable scanning fluorescence quantitative analysis platform for near-patient testing.

"This is a very important agreement for Response as it marks a significant step into the US market for POCT in the cardiovascular arena, which is one of the largest markets in the world," Tim Shannon, senior vice president of worldwide sales and marketing for Vancouver, British Columbia-based Response Biomed, said in a statement. "We believe that LABSCO has the experience and reputation to maximize our efforts to gain traction and to help us penetrate a market that we believe will greatly enhance our growth in the near term and beyond."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.